NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Down 75.9% in February

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) was the recipient of a significant decrease in short interest in February. As of February 27th, there was short interest totaling 926,133 shares, a decrease of 75.9% from the February 12th total of 3,839,273 shares. Based on an average daily trading volume, of 665,099 shares, the short-interest ratio is presently 1.4 days. Currently, 6.4% of the shares of the company are sold short. Currently, 6.4% of the shares of the company are sold short. Based on an average daily trading volume, of 665,099 shares, the short-interest ratio is presently 1.4 days.

Hedge Funds Weigh In On NovaBay Pharmaceuticals

Large investors have recently bought and sold shares of the business. Ground Swell Capital LLC purchased a new position in NovaBay Pharmaceuticals during the third quarter worth approximately $25,000. Apollon Wealth Management LLC purchased a new stake in shares of NovaBay Pharmaceuticals in the third quarter valued at approximately $35,000. ExodusPoint Capital Management LP purchased a new stake in shares of NovaBay Pharmaceuticals in the fourth quarter valued at approximately $114,000. OMERS ADMINISTRATION Corp acquired a new position in shares of NovaBay Pharmaceuticals during the 4th quarter worth approximately $120,000. Finally, C2C Wealth Management LLC purchased a new position in shares of NovaBay Pharmaceuticals during the 4th quarter valued at approximately $254,000. Institutional investors and hedge funds own 23.25% of the company’s stock.

NovaBay Pharmaceuticals Price Performance

NBY stock traded up $0.02 during midday trading on Tuesday, hitting $1.26. 320,912 shares of the stock traded hands, compared to its average volume of 477,805. NovaBay Pharmaceuticals has a 1-year low of $1.11 and a 1-year high of $99.75. The stock’s fifty day simple moving average is $20.65 and its 200-day simple moving average is $13.35. The firm has a market cap of $32.66 million, a P/E ratio of -0.13 and a beta of 0.25.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company’s synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay’s research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.

The company’s primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.